PKO Investment Management Joint Stock Co Sells 1,900 Shares of Amgen Inc. $AMGN

PKO Investment Management Joint Stock Co trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,600 shares of the medical research company’s stock after selling 1,900 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Amgen were worth $7,952,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Dogwood Wealth Management LLC raised its position in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares in the last quarter. Anfield Capital Management LLC boosted its position in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in Amgen during the fourth quarter valued at about $26,000. Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new position in Amgen in the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on AMGN. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research report on Thursday. Daiwa Securities Group reduced their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Mizuho raised their target price on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research note on Tuesday, June 16th. Finally, The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $354.42.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $344.72 on Tuesday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a market cap of $186.05 billion, a PE ratio of 23.99, a P/E/G ratio of 3.39 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The business has a 50-day simple moving average of $340.50 and a two-hundred day simple moving average of $345.86.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.